Over the past few months, BioLargo pivoted to develop and deliver solutions to help combat the COVID-19 pandemic, including Clyraguard Personal Protection Spray, manufactured and sold by our subsidiary Clyra Medical Technologies. At the outset of the pandemic, we recognized that our iodine-based technologies would make a meaningful contribution to the fight against SARS-CoV-2 (the virus that causes COVID-19). Our response is directly in line with our mission statement to “make life better” because nothing is more important right now than helping protect people against this virus.
Last week at the 27th Octane High Tech Awards, BioLargo was honored for its contribution to the fight against COVID with a “COVID-19 Response Recognition Award”. We thank the Octane team for this honor, and we are humbled to have been recognized among such incredible Orange County based innovators.
The award highlighted BioLargo’s agile response to COVID. They noted that the company’s subsidiary Clyra Medical Technologies worked quickly to roll out Clyraguard Personal Protection Spray (www.clyramedical.com/clyraguard), which recently launched to great enthusiasm, with sales and distribution presently ramping up through national partners.
Clyraguard, an FDA-registered hospital-grade disinfectant, offers an additional line of defense against COVID-19. It helps protects mask-wearers from cross contamination by providing quick, safe, effective on-the-go decontamination of masks and other noncritical PPE. It has been tested and proven effective to completely inactivate SARS-CoV-2 (COVID-19) in a published study conducted by Galveston National Lab (UTMB-Galveston), and it is proven to be non-toxic, non-irritating, non-sensitizing, safe on skin, and eco-friendly.
Launching this product was no easy task – Clyra set up contract manufacturing capable of delivering up to 1 million units per month, secured FDA registration, built a full-scale marketing campaign that is currently launching, and established partnerships with national distributors.
BioLargo also advanced its proprietary iodine technology to be used as an environmental disinfectant. Already, third-party studies were that proved the product, derived from BioLargo’s CupriDyne® technology, achieving complete inactivation against SARS-CoV-2 in only 10 minutes.
This award is not the first time that BioLargo has been honored by Octane at their HTA event. In 2017, BioLargo received an Octane award for Horizontal Disruption because of the company’s diverse innovative life sciences technologies. The following year, BioLargo CEO Dennis P. Calvert was invited to be a judge for the 2018 HTA awards alongside decorated entrepreneur Shawn Dougherty (who is now Clyra Medical Technologies’ Chief Revenue Officer). We believe organizations like Octane, which is Orange County's premier tech incubator, are crucial in times like these, as they promote the advancement of critically important innovative technologies that help make people’s lives better.
On a Clyraguard-related note – we are anxious to update everyone on the advancement of Clyraguard sales, so keep an eye out for more Clyraguard news!